| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0213-005X(11)70005-2 |
| P698 | PubMed publication ID | 21420573 |
| P2093 | author name string | José Tomás Ramos Amador | |
| Sara Guillén Martín | |||
| Luis Prieto Tato | |||
| P2860 | cites work | Pharmacokinetics of an elevated dosage of micafungin in premature neonates | Q30436332 |
| Population pharmacokinetics of micafungin in neonates and young infants | Q33876608 | ||
| Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients | Q34022906 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Mycoses in pediatric patients | Q36598063 | ||
| Treatment of invasive candidal infections: systematic review and meta-analysis | Q37262242 | ||
| Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients | Q37535957 | ||
| A clinical review of echinocandins in pediatric patients | Q37653647 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants | Q42604806 | ||
| Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. | Q43024375 | ||
| Prospective study on fungemia in children with cancer: analysis of 35 cases and comparison with 130 fungemias in adults | Q44580522 | ||
| Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. | Q44984663 | ||
| Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. | Q45918306 | ||
| Antifungal prophylaxis with micafungin in patients treated for childhood cancer. | Q45966046 | ||
| [Micafungin in pediatric and adolescent patients]. | Q46000241 | ||
| Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial | Q46446545 | ||
| Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months | Q47354614 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections | Q80036620 | ||
| P304 | page(s) | 23-28 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Infectious Diseases and Clinical Microbiology | Q15766978 |
| P1476 | title | [Why might micafungin be the drug of choice in pediatric patients?] | |
| P478 | volume | 29 Suppl 2 |
| Q27004496 | Management strategies in the treatment of neonatal and pediatric gastroenteritis | cites work | P2860 |
Search more.